Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Pharma M&A: It's Back

Pfizer's desire to buy AstraZeneca is the biggest deal that's getting the most attention in the pharma space, but they aren't the only large drugmakers hooking up.

Last week, Novartis (NYSE: NVS  ) and GlaxoSmithKline (NYSE: GSK  ) traded products, sending Novartis' vaccines to GlaxoSmithKline and Glaxo's cancer drugs to Novartis. And the duo formed a joint venture to sell the companies' over-the-counter products. Not to be left out, Eli Lilly (NYSE: LLY  ) picked up Novartis' animal health business.

On the deal-rumor side, Merck (NYSE: MRK  ) is reportedly looking for a buyer for its consumer health-care unit. Bayer and Reckitt Benckiser appear to be the top contenders for the unit that could go for roughly $13.5 billion.

In the video below, senior biotech specialist Brian Orelli and health care analyst David Williamson discuss the activity in the pharma space as well as why we get so many rumors from "people familiar with the matter" discussing potential deals with the press.

Let's hope consolidation doesn't result in cut dividends
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2940150, ~/Articles/ArticleHandler.aspx, 9/4/2015 7:09:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:00 PM
GSK $39.69 Down -0.93 -2.29%
GlaxoSmithKline CAPS Rating: ****
LLY $80.32 Down -1.28 -1.57%
Eli Lilly & Co. CAPS Rating: ****
MRK $51.59 Down -1.06 -2.01%
Merck & Co., Inc. CAPS Rating: ****
NVS $94.55 Down -0.81 -0.85%
Novartis CAPS Rating: ****